Kinase target engagement is a new way to study kinase inhibitors for target selectivity, potency and residency. The NanoBRET™ TE Intracellular Kinase Assays enable you to quantitate kinase-inhibitor binding in live cells, making these assays an exciting new tool for kinase drug discovery research.

For today’s blog about NanoBRET™ TE Intracellular Kinase Assay, we feature spokesperson Dr. Matt Robers. Matt is part of Promega’s R & D department and is one of the developers of the NanoBRET™ TE Intracellular Kinase Assay.

Matt was recorded at SLAS earlier this year. Here is the video:

If you’d like to learn more about the NanoBRET™ TE Intracellular Kinase Assays, the product page contains assay data and a table of the 127 full-length kinases currently available. Additional NanoBRET TE kinase assays are available through Promega Custom Assay Services . We can also make an assay for your specific target.

You will also want to read the Cell Chemical Biology publication by Vasta, Robers, et al. (2017) on the product page for more details on the capabilities of the NanoBRET™ TE Kinase Assays.

Our thanks to LabTube for permission to reuse this video.

The following two tabs change content below.

• Bio
• Latest Posts

Kari Kenefick

Kari has been a science writer/editor for Promega since 1996. Prior to that she enjoyed working in veterinary microbiology/immunology, and has an M.S. in Bacteriology, U of WI-Madison. Favorite topics include infectious disease, inflammation, aging, exercise, nutrition and personality traits. When not writing, she enjoys training her dogs in agility and obedience. About the practice of writing, as we say for cell-based assays, "add-mix-measure".

Latest posts by Kari Kenefick (see all)

• Made Just for You: Promega Custom Reagents - October 28, 2022
• Real-Time Analysis for Cell Viability, Cytotoxicity and Apoptosis: What Would You Do with More Data from One Sample? - January 25, 2022
• Evidence of Inflammasome Activation in Severe COVID-19 - September 22, 2021